A Phase 1 Study of PBCAR19B in Subjects with CD19-expressing Malignancies
Dose-escalation Safety Study of PBCAR19B in Participants With CD19-expressing Malignancies (Non Hodgkin Lymphoma)
Sponsor: Precision BioSciences, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAT5943
U.S. Govt. ID: NCT04649112
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this research study is to obtain information on the safety and effectiveness of PBCAR19B to treat certain types of cancers. PBCAR19B is a new investigational treatment for certain types of cancer of the blood, such as leukemia and lymphoma. It is made from a type of blood cells known as T cells. The T cells in PBCAR19B came from healthy people who have donated their blood. The donated T cells have been genetically changed, so that they may be able to kill some types of cancer cells.
This study is closed
Investigator
Ran Reshef, MD
Do You Qualify?
Are you age 18 or older? Yes No
Do you have lymphoma that has come back or not responded to treatment? Yes No
Are you able and willing to provide written informed consent? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE